Barcelona, Dec 3, 2018 - Sagetis Biotech is pleased to announce that Sagetis’ Chief Executive Officer, Eduard Diviu and R&D Head, Dr. Anna Cascante, will be attending Annual Oncolytic Virotherapy Summit in Boston (USA) from the 4th - 6th December 2018. Additionally, Dr. Anna Cascante will also give a presentation titled “Viroshield™: An Innovative Polymeric Coating Technology to Enable Systemic Delivery of Oncolytic Viruses” on Tuesday, Dec 6 at 2:00 pm (Boston local time). If you wish to meet Eduard (email@example.com) or Anna (firstname.lastname@example.org), please let them know .
About Oncolytic Virotherapy Summit
The 4th Annual Oncolytic Virotherapy Summit continues to be the industry leading forum dedicated exclusively to advancing clinically and commercially successful
The 4th Oncolytic Virotherapy Summit is the leading resource for biotech and pharma drug developers to gain scientific and clinical trial updates, discuss current challenges and network with senior leaders in the oncolytic virotherapy field. With a case-study led agenda and a technical focus on novel combination OV approaches, such as CAR-T, immune checkpoint inhibitors and current standard of care, it is a chance to join the thought leaders to find the most fitting niche for OVs in the immuno-oncology space. The OV Summit 2018 aims to be a guide through the global regulatory landscape, optimize manufacturing platforms and boost investment in the field.
About Sagetis Biotech
Sagetis Biotech is devoted to developing an innovative gene delivery technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors. Privately funded and based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.